This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 2 of 3 for:    ofatumumab nhl 9

Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen (COMPLEMENT A+B)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01077518
First received: February 25, 2010
Last updated: May 25, 2017
Last verified: May 2017
  Purpose
The purpose of this study is to evaluate the safety and efficacy of ofatumumab and bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab treatment.

Condition Intervention Phase
Lymphoma, Follicular Drug: Ofatumumab and Bendamustine infusions (Arm A) Drug: Bendamustine infusion (Arm B) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: No masking
Primary Purpose: Treatment
Official Title: A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Progression-free-survival following ofatumumab and bendamustine combination therapy [ Time Frame: 68 months ]

Secondary Outcome Measures:
  • Clinical benefit, changes in patient reported outcome measures, and pharmacokinetics following ofatumumab and bendamustine combination therapy [ Time Frame: 62 months ]
  • Overall response rate, overall survival, time to and duration of response following ofatumumab and bendamustine combination therapy [ Time Frame: 62 months ]
  • Safety and tolerability of ofatumumab and bendamustine combination therapy [ Time Frame: 62 months ]

Enrollment: 346
Actual Study Start Date: August 26, 2010
Estimated Study Completion Date: July 18, 2023
Estimated Primary Completion Date: August 30, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ofatumumab and Bendamustine (Arm A)
Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
Drug: Ofatumumab and Bendamustine infusions (Arm A)
Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
Active Comparator: Bendamustine (Arm B)
Up o 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
Drug: Bendamustine infusion (Arm B)
Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).

Detailed Description:

Ofatumumab is an anti-CD20 monoclonal antibody shown to have monotherapy activity in patients with follicular lymphoma that has relapsed following rituximab-containing therapy. Bendamustine was approved by FDA for the treatment of in patients with indolent B-cell Non-Hodgkin's Lymphoma (NHL) that did not respond to rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab treatment.

Biologics have demonstrated enhanced efficacy when added to chemotherapeutic combinations in the frontline treatment for indolent NHL. The combination of ofatumumab and bendamustine may provide additional clinical benefit and efficacy to those who no longer respond to rituximab or rituximab-containing regimens.

The objective of this study is to determine the effect of ofatumumab and bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indolent lymphoma including Grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; Stages III-IV, or bulky disease, Stage II. Tumor verified CD20+ and CT imaging done at screening verifying disease
  • Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen
  • Indolent lymphoma including grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage II (i.e. as any single mass > 5 cm in any direction)
  • ECOG Performance Status of 0, 1, or 2
  • Life expectancy of at least 6 months
  • 18 years or older
  • Signed, written informed consent

Exclusion Criteria:

  • Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma
  • Previous allogeneic stem cell transplant
  • Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months
  • Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies
  • High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomization
  • Prior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 months
  • Treatment with anti-CD20 monoclonal antibody within 3 months of randomization
  • Known CNS involvement of indolent lymphoma
  • Other past or current malignancy. Subjects free of malignancy for at least 5 years or have history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
  • Clinically significant cardiac disease
  • History of significant cerebrovascular disease or event with significant symptoms
  • Positive serology for Hepatitis B
  • Current active liver or biliary disease (except Gibler's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease)
  • Known HIV positive
  • Abnormal/inadequate blood values, liver and kidney function
  • Current participation in other clinical study
  • Inability to comply with the protocol activities
  • Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01077518

  Hide Study Locations
Locations
United States, Arizona
Novartis Investigative Site
Tucson, Arizona, United States, 85715
United States, California
Novartis Investigative Site
Beverly Hills, California, United States, 90211
Novartis Investigative Site
Palm Springs, California, United States, 92262
United States, District of Columbia
Novartis Investigative Site
Washington, D.C., District of Columbia, United States, 20037
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30341
United States, Idaho
Novartis Investigative Site
Coeur d'Alene, Idaho, United States, 83814
United States, Maryland
Novartis Investigative Site
Silver Spring, Maryland, United States, 21044
United States, Michigan
Novartis Investigative Site
Detroit, Michigan, United States, 48202
United States, Missouri
Novartis Investigative Site
Saint Louis, Missouri, United States, 63141
United States, New York
Novartis Investigative Site
Mineola, New York, United States, 11501
Novartis Investigative Site
Rochester, New York, United States, 14642
United States, Pennsylvania
Novartis Investigative Site
Danville, Pennsylvania, United States, 17822
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19106
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29425
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
United States, Virginia
Novartis Investigative Site
Richmond, Virginia, United States, 23230
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98108
United States, West Virginia
Novartis Investigative Site
Morgantown, West Virginia, United States, 26506
Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina, C1417DTN
Novartis Investigative Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1431FWO
Novartis Investigative Site
Derqui, Pilar, Buenos Aires, Argentina, B1629AHJ
Novartis Investigative Site
La Plata, Buenos Aires, Argentina, B1900AXI
Novartis Investigative Site
Ciudad Autonoma de Buenos Aires, Argentina, C1437JCP
Austria
Novartis Investigative Site
Graz, Austria, 8036
Novartis Investigative Site
Innsbruck, Austria, 6020
Novartis Investigative Site
Leoben, Austria, 8700
Novartis Investigative Site
Linz, Austria, 4020
Novartis Investigative Site
Salzburg, Austria, A-5020
Novartis Investigative Site
Steyr, Austria, 4400
Novartis Investigative Site
Wien, Austria, 1090
Belgium
Novartis Investigative Site
Brugge, Belgium, 8000
Novartis Investigative Site
Brussels, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Brazil
Novartis Investigative Site
Jau, São Paulo, Brazil, 17210-080
Novartis Investigative Site
Sao Paulo, São Paulo, Brazil, 04039-901
Novartis Investigative Site
Brasila/DF, Brazil, 70.390-055
Novartis Investigative Site
Rio de Janeiro, Brazil, 20230 -130
Novartis Investigative Site
Sao Paulo - SP, Brazil, 01323-900
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 4N2
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Novartis Investigative Site
Barrie, Ontario, Canada, L4M 6M2
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Saskatchewan
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
France
Novartis Investigative Site
Avignon cedex 9, France, 84902
Novartis Investigative Site
Clermont-Ferrand Cedex 1, France, 63003
Novartis Investigative Site
Grenoble cedex 9, France, 38043
Novartis Investigative Site
La Roche sur Yon Cedex 9, France, 85925
Novartis Investigative Site
Le Mans, France, 72015
Novartis Investigative Site
Marseille Cedex 9, France, 13273
Novartis Investigative Site
Nantes cedex 1, France, 44093
Novartis Investigative Site
Pessac cedex, France, 33604
Novartis Investigative Site
Saint Pierre cedex, France, 97448
Novartis Investigative Site
Saint-Denis cedex, France, 97405
Novartis Investigative Site
Saint-Herblain cedex, France, 44805
Novartis Investigative Site
Tours cedex 9, France, 37044
Germany
Novartis Investigative Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
Novartis Investigative Site
Aschaffenburg, Bayern, Germany, 63739
Novartis Investigative Site
Fuerth, Bayern, Germany, 90766
Novartis Investigative Site
Muenchen, Bayern, Germany, 80335
Novartis Investigative Site
Muenchen, Bayern, Germany, 81241
Novartis Investigative Site
Weilheim, Bayern, Germany, 82362
Novartis Investigative Site
Frankfurt, Hessen, Germany, 60488
Novartis Investigative Site
Giessen, Hessen, Germany, 35392
Novartis Investigative Site
Hanau, Hessen, Germany, 63450
Novartis Investigative Site
Kassel, Hessen, Germany, 34119
Novartis Investigative Site
Marburg, Hessen, Germany, 35037
Novartis Investigative Site
Bielefeld, Nordrhein-Westfalen, Germany, 33604
Novartis Investigative Site
Bottrop, Nordrhein-Westfalen, Germany, 46236
Novartis Investigative Site
Essen, Nordrhein-Westfalen, Germany, 45122
Novartis Investigative Site
Goch, Nordrhein-Westfalen, Germany, 47574
Novartis Investigative Site
Herford, Nordrhein-Westfalen, Germany, 32049
Novartis Investigative Site
Leverkusen, Nordrhein-Westfalen, Germany, 51375
Novartis Investigative Site
Paderborn, Nordrhein-Westfalen, Germany, 33098
Novartis Investigative Site
Recklinghausen, Nordrhein-Westfalen, Germany, 45657
Novartis Investigative Site
Kaiserslautern, Rheinland-Pfalz, Germany, 67655
Novartis Investigative Site
Koblenz, Rheinland-Pfalz, Germany, 56068
Novartis Investigative Site
Neunkirchen, Saarland, Germany, 66538
Novartis Investigative Site
Berlin, Germany, 12200
Novartis Investigative Site
Bremen, Germany, 28239
Greece
Novartis Investigative Site
Alexandroupolis, Greece, 68100
Novartis Investigative Site
Athens,, Greece, 11 527
Novartis Investigative Site
Athens, Greece, 106 76
Novartis Investigative Site
Haidari, Athens, Greece, 12462
Novartis Investigative Site
Heraklion, Crete, Greece, 71201
Novartis Investigative Site
Ioannina, Greece, 45 500
Novartis Investigative Site
Piraeus, Greece, 18537
Hong Kong
Novartis Investigative Site
Shatin, New Territories, Hong Kong
Novartis Investigative Site
Tuen Mun, Hong Kong
Italy
Novartis Investigative Site
Reggio Calabria, Calabria, Italy, 89100
Novartis Investigative Site
Napoli, Campania, Italy, 80131
Novartis Investigative Site
Meldola (FC), Emilia-Romagna, Italy, 47014
Novartis Investigative Site
Roma, Lazio, Italy, 00168
Novartis Investigative Site
Genova, Liguria, Italy, 16132
Novartis Investigative Site
Milano, Lombardia, Italy, 20133
Novartis Investigative Site
Milano, Lombardia, Italy, 20162
Novartis Investigative Site
Novara, Piemonte, Italy, 28100
Novartis Investigative Site
San Giovanni Rotondo, Puglia, Italy, 71013
Novartis Investigative Site
Terni, Umbria, Italy, 05100
Novartis Investigative Site
Verona, Veneto, Italy, 37134
Japan
Novartis Investigative Site
Aichi, Japan, 466-8650
Novartis Investigative Site
Fukuoka, Japan, 810-8563
Novartis Investigative Site
Hiroshima, Japan, 737-0023
Novartis Investigative Site
Hyogo, Japan, 670-8520
Novartis Investigative Site
Ibaraki, Japan, 305-8576
Novartis Investigative Site
Kanagawa, Japan, 259-1143
Novartis Investigative Site
Miyagi, Japan, 980-8574
Novartis Investigative Site
Okayama, Japan, 710-8602
Novartis Investigative Site
Osaka, Japan, 545-8586
Novartis Investigative Site
Tokyo, Japan, 104-0045
Novartis Investigative Site
Tokyo, Japan, 135-8550
Poland
Novartis Investigative Site
Gdansk, Poland, 80-952
Novartis Investigative Site
Gdynia, Poland
Novartis Investigative Site
Legnica, Poland, 59-200
Novartis Investigative Site
Opole, Poland, 45-061
Novartis Investigative Site
Warszawa, Poland, 02-097
Novartis Investigative Site
Warszawa, Poland, 02-507
Novartis Investigative Site
Warszawa, Poland, 02-776
Novartis Investigative Site
Warszawa, Poland
Novartis Investigative Site
Wroclaw, Poland, 50-367
Novartis Investigative Site
Wroclaw, Poland, 53-439
Puerto Rico
Novartis Investigative Site
Hato Rey, Puerto Rico, 00919
Novartis Investigative Site
San Juan, Puerto Rico, 00927
Russian Federation
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454087
Novartis Investigative Site
Kaluga, Russian Federation, 248007
Novartis Investigative Site
Kazan, Russian Federation, 420029
Novartis Investigative Site
Moscow, Russian Federation, 115478
Novartis Investigative Site
Nizhniy Novgorod, Russian Federation, 603126
Novartis Investigative Site
Novosibirsk, Russian Federation, 630087
Novartis Investigative Site
Penza, Russian Federation, 440071
Novartis Investigative Site
St'Petersburg, Russian Federation, 197341
Novartis Investigative Site
St. Petersburg, Russian Federation, 197758
Novartis Investigative Site
Tula, Russian Federation, 300053
Novartis Investigative Site
Ufa,, Russian Federation, 450054
Novartis Investigative Site
Volgograd, Russian Federation, 400138
Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 833 10
Ukraine
Novartis Investigative Site
Kyiv, Ukraine, 03022
Novartis Investigative Site
Lviv, Ukraine, 79044
Novartis Investigative Site
Makiivka, Ukraine, 86132
United Kingdom
Novartis Investigative Site
Plymouth, Devon, United Kingdom, PL68DH
Novartis Investigative Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Novartis Investigative Site
Harrow, United Kingdom, HA1 3UJ
Novartis Investigative Site
Southampton, United Kingdom, SO16 6YD
Novartis Investigative Site
Uxbridge, United Kingdom, UB8 3NN
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01077518     History of Changes
Other Study ID Numbers: 110918
Study First Received: February 25, 2010
Last Updated: May 25, 2017
Individual Participant Data  
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Refractory
Safety
Efficacy
Rituximab refractory
Oncology

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Follicular
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Bendamustine Hydrochloride
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 26, 2017